Page 12 - Read Online

Table 1: A brief summary of previous reports of CR cases such an approach can be regarded as safe, and thereby
treated with sorafenib as a monotherapy for HCC improves quality-of-life and reduces treatment costs for
References CR Duration of Relapse patients in which a CR is achieved.
cases treatment cessation
(months)
Financial support and sponsorship
So et al. [7] 1 6 No
Kudo and Ueshima [5] 15 NA No Nil.
Wang et al. [8] 1 16 No
Sacco et al. [9] 1 ≥ 6 No Confl ict of interest
Inuzuka et al. [10] 1 8 No There is no conflict of interest.
CR: complete remission; HCC: hepatocellular carcinoma; NA: not available
REFERENCES
magnetic resonance imaging. Thereafter, he discontinued
sorafenib therapy because he could not afford the treatment 1. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de
cost. Up to April 30, 2015, he had CR of tumor status for Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C,
58 months. Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I,
Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J;
SHARP Investigators Study Group. Sorafenib in advanced hepatocellular
As we know, most patients treated with tyrosine kinase carcinoma. N Engl J Med 2008;359:378-90.
inhibitors (TKIs) would suffer from drug-related adverse 2. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J,
Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H,
effects. Discontinuation of treatment with TKIs could improve Burock K, Zou J, Voliotis D, Guan Z. Effi cacy and safety of sorafenib
quality-of-life and reduce treatment costs for patients in in patients in the Asia-Pacifi c region with advanced hepatocellular
which a CR is achieved. To our knowledge, there are several carcinoma: a phase III randomised, double-blind, placebo-controlled
[6]
case reports concerning this issue [Table 1], and it seems 3. trial. Lancet Oncol 2009;10:25-34.
Zhang L, Hu P, Chen X, Bie P. Transarterial chemoembolization (TACE)
that relapse of tumor hardly happens in patients who have plus sorafenib versus TACE for intermediate or advanced stage
achieved CR after sorafenib monotherapy, irrespective of drug hepatocellular carcinoma: a meta-analysis. PLoS One 2014;9:e100305.
discontinuation or not. For patients who received sorafenib 4. Chao Y, Chung YH, Han G, Yoon JH, Yang J, Wang J, Shao GL, Kim BI,
in combination with other therapeutic means, the CR status Lee TY. The combination of transcatheter arterial chemoembolization
and sorafenib is well tolerated and effective in Asian patients with
may be partly due to the combination treatment, like TACE. hepatocellular carcinoma: fi nal results of the START trial. Int J Cancer
Therefore, we propose that sorafenib should be discontinued 2015;136:1458-67.
to reduce the drug-related adverse effects. However, 5. Kudo M, Ueshima K. Positioning of a molecular-targeted agent,
discontinuation of sorafenib in patients with CR carries sorafenib, in the treatment algorithm for hepatocellular carcinoma and
implication of many complete remission cases in Japan. Oncology
the risk of progression with new metastases and potential 2010;78 Suppl 1:154-66.
complications. Further investigation in a larger cohort of 6. Johannsen M, Flörcken A, Bex A, Roigas J, Cosentino M, Ficarra V,
cases is warranted before such an approach can be regarded Kloeters C, Rief M, Rogalla P, Miller K, Grünwald V. Can tyrosine
kinase inhibitors be discontinued in patients with metastatic renal
as safe. However, this methodology has limitations associated cell carcinoma and a complete response to treatment? A multicentre,
with the small sample of CR cases and interference of other retrospective analysis. Eur Urol 2009;55:1430-8.
therapeutic means, and hence it may just be a hypothesis. 7. So BJ, Bekaii-Saab T, Bloomston MA, Patel T. Complete clinical
response of metastatic hepatocellular carcinoma to sorafenib in a patient
with hemochromatosis: a case report. J Hematol Oncol 2008;1:18.
CONCLUSION 8. Wang SX, Byrnes A, Verma S, Pancoast JR, Rixe O. Complete remission
of unresectable hepatocellular carcinoma treated with reduced dose of
Sorafenib has demonstrated clinical efficacy in HCC patients, sorafenib: a case report. Target Oncol 2010;5:59-63.
and more and more CR cases were reported. For patients 9. Sacco R, Bargellini I, Gianluigi G, Bertini M, Bozzi E, Altomare E,
Battaglia V, Romano A, Bertoni M, Capria A, Bresci G, Bartolozzi C.
who have achieved CR, we propose that sorafenib may Complete response for advanced liver cancer during sorafenib therapy:
be discontinued, irrespective of whether it was used as case report. BMC Gastroenterol 2011;11:4.
monotherapy or combination therapy with other therapeutic 10. Inuzuka T, Nishikawa H, Sekikawa A, Takeda H, Henmi S, Sakamoto A,
means. Evaluation of the current hypothesis and investigation Saito S, Kita R, Kimura T, Osaki Y, Kudo M. Complete response of
advanced hepatocellular carcinoma with multiple lung metastases treated
with a larger cohort of cases may provide information that with sorafenib: a case report. Oncology 2011;81 Suppl 1:152-7.

110 Hepatoma Research | Volume 1 | Issue 3 | October 15, 2015